The Food and Drug Administration (FDA) has approved Arbli™, an oral suspension formulation of losartan potassium.  Arbli, an angiotensin II receptor ...

The Food and Drug Administration (FDA) has approved Arbli ™, an oral suspension formulation of losartan potassium ... adults and children greater than 6 years old; for the reduction of the ...

Losartan is a prescription drug. It comes as an oral tablet ... Child dosage (ages 6 to 17 years) The dosage is based on the child’s weight. The usual dosage is around 0.7 mg per kilogram ...

Scienture shares originally traded higher on Tuesday but have since reversed and began trading lower after the company ...

Actuate Therapeutics' elraglusib shows promise for pancreatic cancer, but financial instability and risks make it a high-risk ...

SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers ...

Scienture (SCNX) announces the U.S. Food and Drug Administration, FDA, has approved SCN-102, one of the products being developed by Scienture, ...

HOLDINGS has completed a draw on its Equity Line of Credit to support the commercial launch of Arbli Oral Suspension, while ...

Additionally, compared with the pill form of losartan, SCN-102 achieved peak concentration earlier ... EAGLE-2, for instance, demonstrated a 50.6% treatment success rate in patients given gepotidacin ...

He reported systolic BP readings in the range of 150 to 170 mm Hg, and diastolic 90 to 110 mm Hg on repeated home BP measurements while being treated with atenolol 50 mg, amlodipine 10 mg, and a ...